William Oh, MD
The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies. Progress in developing biomarker tests is frustratingly slow, according to William K. Oh, MD.
“If AR-V7 testing became more widely available, which it may later this year, then maybe patients who have high levels of AR-V7 would be better candidates for chemotherapy instead of an androgen receptor-targeted treatment,” Oh said.
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038. doi:10.1056/NEJMoa1315815.
... to read the full story